【摘要】 本文报道1例87岁男性患者因新型冠状病毒感染（重型）入院，给予地塞米松联合巴瑞替尼治疗。用药4 d后患者突然无尿，肌酐上升，临床药师考虑为巴瑞替尼引起的急性肾损伤。停用巴瑞替尼并给予补液和利尿治疗，停用7 d后，患者肌酐及尿量恢复至正常范围，后患者未再重启巴瑞替尼治疗。临床药师应参与到临床用药全过程，严密监测，及时发现药品不良反应的发生，并给予正确的处理方案，保障患者的用药安全。更多还原

【Abstract】 A 87-year-old male patient was treated with dexamethasone combined with baricitinib for COVID-19(severe). After 4 days of medication, the patient had no urine and the serum creatinine increased, which was considered as acute kidney injury caused by baritinib by clinical pharmacists. Baricitinib was then immediately discontinued. After diuretic and rehydration treatment, serum creatinine decreased, and the urine output increased. After discontinuation of barritenib and administration of rehydration and diuretic treatment, the patient’s creatinine and urine volume returned to normal range 7 days later, and the patient did not restart barritenib treatment thereafter. Clinical pharmacists should participate in and closely monitor the whole process of medication, detect the occurrence of adverse drug reactions in time, and propose correct treatment plans to ensure the safety of drug use for patients.更多还原